TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Abstract
Purpose: To determine the frequency of TP53 mutations and the level of p53 protein expression by immunohistochemistry (IHC) in low-risk myelodysplastic syndromes (MDS) with del(5q) and to assess their impact on disease progression. Patients and Methods: Pre- and postprogression bone marrow (BM) samples from 55 consecutive patients with International Prognostic Scoring System low risk (n = 32) or intermediate-1 risk (n = 23) were studied by next-generation sequencing of TP53. IHC for p53 was performed on 148 sequential BM samples. Results: TP53 mutations with a median clone size of 11% (range, 1% to 54%) were detected in 10 patients (18%) already at an early phase of the disease. Mutations were equally common in low-risk and intermediate-1–risk patients and were associated with evolution to acute myeloid leukemia (5 of 10 v 7 of 45; P = .045). Nine of 10 patients carrying mutations showed more than 2% BM progenitors with strong p53 staining. The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). Conclusion: By using sensitive deep-sequencing technology, we demonstrated that TP53 mutated populations may occur at an early disease stage in almost a fifth of low-risk MDS patients with del(5q). Importantly, mutations were present years before disease progression and were associated with an increased risk of leukemic evolution. TP53 mutations could not be predicted by common clinical features but were associated with p53 overexpression. Our findings indicate a previously unrecognized heterogeneity of the disease which may significantly affect clinical decision making.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IKZF1 is expressed throughout haematopoiesis and regulates myeloid cell development and function.
“Of note, IKZF1 is expressed throughout haematopoiesis and regulates myeloid cell development and function100.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [100]
When Ck1α is further degraded upon lenalidomide treatment, this results in activation of p53 leading to induction of apoptosis.
“When Ck1α was further degraded upon lenalidomide treatment, this resulted in the activation of p53 leading to the induction of apoptosis.”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [32]
Upon binding of IMiDs to CRBN, original substrates (e.g. MEIS2) of CRBN are spared from ubiquitination and degradation, and accumulate.
“It was also found that upon the binding of IMiDs to CRBN, original substrates (e.g.MEIS2) of CRBN are spared from ubiquitination and degradation, and accumulate [32].”
From Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs (2016) · cites this paper as [32]
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933 · see citing works
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427 · see citing works
Self-citationMalcovati, L., Germing, U., Kuendgen, A., Porta, M. G. D., Pascutto, C., Invernizzi, R., Giagounidis, A. A. N., Hildebrandt, B., BERNASCONI, P. P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,029 · see citing works
Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592 · see citing works
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome
Barlow, J. L., Drynan, L. F., Hewett, D. R., Holmes, L. R., Lorenzo-Abalde, S., Lane, A. L., Jolin, H. E., Pannell, R., Middleton, A. J., Wong, S. H., et al. (2009) · Nature Medicine · doi:10.1038/nm.2063 · Cited by 337 · see citing works
Christiansen, D. H., Andersen, M. K., & Pedersen-Bjergaard, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1405 · Cited by 308 · see citing works
RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up
Padua, R. A., Guinn, B., Al-Sabah, A., Smith, M. T., Taylor, C., Pettersson, T., Ridge, S. A., Carter, G., White, D., Oscier, D. G., et al. (1998) · Leukemia · doi:10.1038/sj.leu.2401044 · Cited by 213 · see citing works
Giagounidis, A. A. N., Germing, U., Haase, S. P., Hildebrandt, B., Schlegelberger, B., Schoch, C., Wilkens, L., Heinsch, M., Willems, H. P. J., Aivado, M. A., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403189 · Cited by 210 · see citing works
Self-citationLaï, J., Preudhomme, C., Zandecki, M., FLACTIF, M., Vanrumbeke, M., Lepelley, P., Wattel, E., & Fenaux, P. (1995) · PubMed · Cited by 197 · see citing works
Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia
Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., & Hirai, H. (1993) · Blood · doi:10.1182/blood.v81.11.3022.3022 · Cited by 123 · see citing works
Kaneko, H., Misawa, S., Horiike, S., Nakai, H., & Kashima, K. (1995) · Blood · doi:10.1182/blood.v85.8.2189.bloodjournal8582189 · Cited by 101 · see citing works
Jädersten, M., Saft, L., Pellagatti, A., Göhring, G., Wainscoat, J. S., Boultwood, J., Porwit‐MacDonald, A., Schlegelberger, B., & Hellström‐Lindberg, E. (2009) · Haematologica · doi:10.3324/haematol.2009.011528 · Cited by 100 · see citing works
Self-citationKita‐Sasai, Y., Horiike, S., Misawa, S., Kaneko, H., Kobayashi, M., Nakao, M., Nakagawa, H., Fujii, H., & Taniwaki, M. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03073.x · Cited by 88 · see citing works
Novel TET2 Mutations Associated With UPD4q24 in Myelodysplastic Syndrome
Mohamedali, A. M., Smith, A., Gäken, J. A., Lea, N. C., Mian, S. A., Westwood, N., Strupp, C., Gattermann, N., Germing, U., & Mufti, G. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6985 · Cited by 83 · see citing works
Self-citationGöhring, G., Giagounidis, A. A. N., Büsche, G., Kreipe, H. H., Zimmermann, M., Hellström‐Lindberg, E., Aul, C., & Schlegelberger, B. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0846-z · Cited by 80 · see citing works
Self-citationLepelley, P., Preudhomme, C., Vanrumbeke, M., Quesnel, B., Cosson, A., & Fenaux, P. (1994) · PubMed · Cited by 76 · see citing works
Kurotaki, H., Tsushima, Y., Nagai, K., & Yagihashi, S. (1999) · Acta Haematologica · doi:10.1159/000040984 · Cited by 63 · see citing works
Side, L. E., Curtiss, N. P., Teel, K., Kratz, C. P., Wang, P. W., Larson, R. A., Beau, M. M. L., & Shannon, K. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10320 · Cited by 62 · see citing works
Kitagawa, M., Yoshida, S., Kuwata, T., Tanizawa, T., & Kamiyama, R. (1994) · PubMed Central · Cited by 50 · see citing works
Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic Syndrome
Horiike, S., Kita‐Sasai, Y., Nakao, M., & Taniwaki, M. (2003) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000067620 · Cited by 49 · see citing works
Lenalidomide: Targeted Anemia Therapy for Myelodysplastic Syndromes
List, A. F., Baker, A. F., Green, S., & Bellamy, W. T. (2006) · Cancer Control · doi:10.1177/107327480601304s02 · Cited by 43 · see citing works
NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler, C., Watkins, F., Bowen, D., Littlewood, T. J., Wainscoat, J. S., & Boultwood, J. (2004) · PubMed · Cited by 40 · see citing works
Melchert, M., Kale, V., & List, A. F. (2007) · Current Opinion in Hematology · doi:10.1097/moh.0b013e328016847a · Cited by 39 · see citing works
P53 mutations in myelodysplastic syndromes.
Ludwig, L., Schulz, A. S., Janssen, J. W. G., Grünewald, K. J. T., & Bartram, C. (1992) · PubMed · Cited by 35 · see citing works
p53 mutation in the myelodysplastic syndromes
Adamson, D. J. A., Dawson, A. A., Bennett, B., King, D. J., & Kingsbury, N. (1995) · British Journal of Haematology · doi:10.1111/j.1365-2141.1995.tb08910.x · Cited by 33 · see citing works
Emerging Data on IMiDs in the Treatment of Myelodysplastic Syndromes (MDS)
List, A. F. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.06.020 · Cited by 33 · see citing works
TP53 Mutations in Myelodysplastic Syndrome
Misawa, S., & Horiike, S. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609054848 · Cited by 32 · see citing works
Iwasaki, T., Murakami, M., Sugisaki, C., Sobue, S., Ohashi, H., Asano, H., Suzuki, M., Nakamura, S., Ito, M., & Murate, T. (2008) · Pathology International · doi:10.1111/j.1440-1827.2008.02236.x · Cited by 29 · see citing works
Orazi, A., Kahsai, M., John, K., & Neiman, R. S. (1996) · PubMed · Cited by 22 · see citing works
Mutations of the p53 gene in myelodysplastic syndrome and overt leukaemia
Mori, N., Hidai, H., Yokota, J., Okada, M., Motoji, T., Oshimi, K., & Mizoguchi, H. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00058-5 · Cited by 18 · see citing works
What does apoptosis have to do with clinical features in myelodysplastic syndrome?
Ramos, F., Fuertes-Núñez, M., Suárez‐Vilela, D., & Fernández‐López, A. (2002) · PubMed · Cited by 13 · see citing works
Rearrangement and expression of the p53 gene in myelodysplastic syndrome and acute myeloid leukemia.
Fenaux, P., D’hooghe, M., Jonveaux, P., Laiê, J. L., Bauters, F., Loucheux, F., & Kerckaert, J. P. (1990) · PubMed · Cited by 11 · see citing works
Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy.
Preudhomme, C., Vanrumbeke, M., Laï, J., Lepelley, P., Wattel, E., & Fenaux, P. (1994) · PubMed · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119 · see citing works
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A. E., ELIAS, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,607 · see citing works
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
Krönke, J., Fink, E. C., Hollenbach, P. W., MacBeth, K. J., Hurst, S. N., Udeshi, N. D., Chamberlain, P. P., Mani, D. R., Man, H. W., Gandhi, A. K., et al. (2015) · Nature · doi:10.1038/nature14610 · Cited by 863 · see citing works
Rücker, F. G., Schlenk, R. F., Bullinger, L., Käyser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2011) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 680 · see citing works
Self-citationMalcovati, L., Hellström‐Lindberg, E., Bowen, D., Adès, L., Čermák, J., del Cañizo, C., Porta, M. G. D., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 667 · see citing works
Self-citationBernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648 · see citing works
Self-citationClonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J. R., Stern, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537167 · Cited by 632 · see citing works
Cazzola, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1904794 · Cited by 496 · see citing works
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 412 · see citing works
Bejar, R. L., Stevenson, K. E., Caughey, B. A., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G. A., Steensma, D. P., Ritz, J., Soiffer, R. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396 · see citing works
Adès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 396 · see citing works
Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis
Makishima, H., Visconte, V., Sakaguchi, H., Jankowska, A. M., Kar, S. A., Jerez, A., Przychodzen, B. P., Bupathi, M., Guinta, K. M., Afable, M. G., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399774 · Cited by 368 · see citing works
Ogawa, S. (2019) · Blood · doi:10.1182/blood-2018-10-844621 · Cited by 366 · see citing works
Yoshizato, T., Nannya, Y., Atsuta, Y., Shiozawa, Y., Iijima‐Yamashita, Y., Yoshida, K., Shiraishi, Y., Suzuki, H., Nagata, Y., Sato, Y., et al. (2017) · Blood · doi:10.1182/blood-2016-12-754796 · Cited by 351 · see citing works
The genetic basis of myelodysplasia and its clinical relevance
Cazzola, M., Porta, M. G. D., & Malcovati, L. (2013) · Blood · doi:10.1182/blood-2013-09-381665 · Cited by 345 · see citing works
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Woll, P. S., Kjällquist, U., Chowdhury, O., Doolittle, H., Wedge, D. C., Thongjuea, S., Erlandsson, R., Ngara, M., Anderson, K., Deng, Q., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.036 · Cited by 317 · see citing works
Self-citationClonal diversity of recurrently mutated genes in myelodysplastic syndromes
Walter, M. J., Shen, D., Shao, J., Ding, L., White, B. S., Kandoth, C., Miller, C. A., Niu, B., McLellan, M. D., Dees, N. D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.58 · Cited by 284 · see citing works
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G. S., Brown, J., Lau, A., Pratt, G., et al. (2015) · Blood · doi:10.1182/blood-2015-05-644872 · Cited by 281 · see citing works
for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259 · see citing works
Self-citationPorta, M. G. D., Gallì, A., Bacigalupo, A. P., Zibellini, S., Bernardi, M., Rizzo, E., Allione, B., Lint, M. T. V., Pioltelli, P. E., Marenco, P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3616 · Cited by 255 · see citing works
Malcovati, L., Papaemmanuil, E., Ambaglio, I., Elena, C., Gallì, A., Porta, M. G. D., Travaglino, E., Pietra, D., Pascutto, C., Ubezio, M., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560227 · Cited by 251 · see citing works
Diagnosis and classification of hematologic malignancies on the basis of genetics
Taylor, J., Xiao, W., & Abdel-Wahab, O. I. (2017) · Blood · doi:10.1182/blood-2017-02-734541 · Cited by 251 · see citing works
Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250 · see citing works
Self-citationStengel, A., Kern, W., Haferlach, T., Meggendorfer, M., Fasan, A., & Haferlach, C. (2016) · Leukemia · doi:10.1038/leu.2016.263 · Cited by 244 · see citing works
Platzbecker, U. (2019) · Blood · doi:10.1182/blood-2018-10-844696 · Cited by 237 · see citing works
Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231 · see citing works
Self-citationMyelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management
Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 229 · see citing works
The novel mechanism of lenalidomide activity
Fink, E. C., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-07-567958 · Cited by 213 · see citing works
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 205 · see citing works
Myelodysplastic syndromes: Contemporary review and how we treat
Gangat, N., Patnaik, M. M., & Tefferi, A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24253 · Cited by 191 · see citing works
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Garcia‐Manero, G., Chien, K. S., & Bravo, G. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 187 · see citing works
Role of ribosomal protein mutations in tumor development (Review)
Goudarzi, K. M., & Lindström, M. S. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3387 · Cited by 177 · see citing works
Genetics of progression from MDS to secondary leukemia
Menssen, A. J., & Walter, M. J. (2020) · Blood · doi:10.1182/blood.2019000942 · Cited by 175 · see citing works
Recent developments in myelodysplastic syndromes
Bejar, R. L., & Steensma, D. P. (2014) · Blood · doi:10.1182/blood-2014-04-522136 · Cited by 173 · see citing works
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia‐Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 173 · see citing works
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fenaux, P., Haase, D. T., Sanz, G. F., Santini, V., & Buske, C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu180 · Cited by 171 · see citing works
Mouhieddine, T. H., Sperling, A. S., Redd, R. A., Park, J., Leventhal, M. J., Gibson, C. J., Manier, S., Nassar, A. H., Capelletti, M., Huynh, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16805-5 · Cited by 171 · see citing works
Fenaux, P., Haase, D. T., Santini, V., Sanz, G. F., Platzbecker, U., & Mey, U. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.002 · Cited by 172 · see citing works
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
Kennedy, J. A., & Ebert, B. L. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0806 · Cited by 170 · see citing works
The relationship between the nucleolus and cancer: Current evidence and emerging paradigms
Oršolić, I., Jurada, D., Pullen, N., Oren, M., Eliopoulos, A. G., & Volarević, S. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.12.004 · Cited by 166 · see citing works
Bally, C., Adès, L., Renneville, A., Sebert, M., Eclache, V., Preudhomme, C., Mozziconacci, M.-J., de The, H., Lehmann-Che, J., & Fenaux, P. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.012 · Cited by 162 · see citing works
Cazzola, M. (2016) · Blood · doi:10.1182/blood-2016-03-657379 · Cited by 155 · see citing works
Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis
Bursać, S., Brdovčak, M. C., Donati, G., & Volarević, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.08.014 · Cited by 154 · see citing works
Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms
Sperling, A. S., Guerra, V. A., Kennedy, J. A., Yan, Y., Hsu, J. I., Wang, F., Nguyen, A. T., Miller, P. G., McConkey, M. E., Barrios, V. A. Q., et al. (2022) · Blood · doi:10.1182/blood.2021014956 · Cited by 151 · see citing works
Clonal evolution in myelodysplastic syndromes
da Silva-Coelho, P., Kroeze, L. I., Yoshida, K., Koorenhof‐Scheele, T. N., Knops, R., van de Locht, L. T., de Graaf, A. O., Massop, M., Sandmann, S., Dugas, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15099 · Cited by 150 · see citing works
How we treat lower-risk myelodysplastic syndromes
Fenaux, P., & Adès, L. (2013) · Blood · doi:10.1182/blood-2013-02-453068 · Cited by 148 · see citing works
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
Jan, M., Sperling, A. S., & Ebert, B. L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00479-z · Cited by 137 · see citing works
Saft, L., Karimi, M., Ghaderi, M., Matolcsy, A., Mufti, G. J., Kulasekararaj, A. G., Göhring, G., Giagounidis, A. A. N., Selleslag, D., Muus, P., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.098103 · Cited by 137 · see citing works
Self-citationMaslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132 · see citing works
Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Fink, E. C., McConkey, M., Adams, D. N., Haldar, S. D., Kennedy, J. A., Guirguis, A. A., Udeshi, N. D., Mani, D. R., Chen, M., Liddicoat, B., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852798 · Cited by 131 · see citing works
Sievers, Q. L., Gasser, J. A., Cowley, G. S., Fischer, E. S., & Ebert, B. L. (2018) · Blood · doi:10.1182/blood-2018-01-821769 · Cited by 124 · see citing works
Clinical Implications of Clonal Hematopoiesis
Steensma, D. P. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.002 · Cited by 124 · see citing works
The molecular pathogenesis of the myelodysplastic syndromes
Pellagatti, A., & Boultwood, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12515 · Cited by 116 · see citing works
Genetic abnormalities and pathophysiology of MDS
Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 108 · see citing works
Mutations of myelodysplastic syndromes (MDS): An update
Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 105 · see citing works
Wei, S., Chen, X., McGraw, K. L., Zhang, L., Komrokji, R. S., Clark, J., Cáceres, G., Billingsley, D., Sokol, L., Lancet, J. E., et al. (2012) · Oncogene · doi:10.1038/onc.2012.139 · Cited by 102 · see citing works
Clinical and genetic predictors of prognosis in myelodysplastic syndromes
Bejar, R. L. (2014) · Haematologica · doi:10.3324/haematol.2013.085217 · Cited by 102 · see citing works
Takahashi, K., Patel, K. P., Bueso-Ramos, C., Zhang, J., Gumbs, C. E., Jabbour, E. J., Kadia, T. M., Andreff, M., Konopleva, M. Y., Dinardo, C. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7290 · Cited by 101 · see citing works
How we manage adults with myelodysplastic syndrome
Fenaux, P., Platzbecker, U., & Adès, L. (2019) · British Journal of Haematology · doi:10.1111/bjh.16206 · Cited by 99 · see citing works
Guidelines for the diagnosis and management of adult myelodysplastic syndromes
Killick, S. B., Carter, C., Culligan, D. J., Dalley, C. D., Das-Gupta, E. P., Drummond, M. W., Enright, H., Jones, G. L., Kell, J., Mills, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12694 · Cited by 96 · see citing works
Self-citationTranslation factors and ribosomal proteins control tumor onset and progression: how?
Loreni, F., Mancino, M., & Biffo, S. (2013) · Oncogene · doi:10.1038/onc.2013.153 · Cited by 90 · see citing works
Li, H., Hu, F., Gale, R. P., Sekeres, M. A., & Liang, Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00402-5 · Cited by 89 · see citing works
Current therapy of myelodysplastic syndromes
Zeidan, A. M., Linhares, Y. P. L., & Gore, S. D. (2013) · Blood Reviews · doi:10.1016/j.blre.2013.07.003 · Cited by 86 · see citing works
Mallo, M., Rey, M. D., Ibáñez, M., Calasanz, M. J., Arenillas, L., Larráyoz, M. J., Pedro, C., Jerez, A., Maciejewski, J. P., Costa, D., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12354 · Cited by 85 · see citing works
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Ito, T., & Handa, H. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2073-4 · Cited by 84 · see citing works
Fang, J., Liu, X., Bolanos, L., Barker, B., Rigolino, C., Cortelezzi, A., Oliva, E. N., Cuzzola, M., Grimes, H. L., Fontanillo, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4127 · Cited by 83 · see citing works
Kar, S. A., Jankowska, A., Makishima, H., Visconte, V., Jerez, A., Sugimoto, Y., Muramatsu, H., Traina, F., Afable, M. G., Guinta, K. M., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.064048 · Cited by 83 · see citing works
Myelodysplastic Syndrome Updated
Hasserjian, R. P. (2018) · Pathobiology · doi:10.1159/000489702 · Cited by 81 · see citing works
Sebaa, A., Adès, L., Baran‐Marszak, F., Mozziconacci, J., Penther, D., Dobbelstein, S., Stamatoullas, A., Récher, C., Prébet, T., Moulessehoul, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21993 · Cited by 81 · see citing works
on behalf of the International Working Group on MDS with del(5q), Kuendgen, A., Lauseker, M., List, A. F., Fenaux, P., Giagounidis, A. A. N., Brandenburg, N. A., Backstrom, J. T., Glasmacher, A., Hasford, J., et al. (2012) · Leukemia · doi:10.1038/leu.2012.369 · Cited by 80 · see citing works
Mian, S. A., Smith, A., Kulasekararaj, A. G., Kizilors, A., Mohamedali, A. M., Lea, N. C., Mitsopoulos, C., Ford, K., Nasser, E. E., Seidl, T., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.075325 · Cited by 77 · see citing works
Self-citationBochtler, T., Stölzel, F., Heilig, C. E., Kunz, C., Mohr, B., Jauch, A. S., Janssen, J. W. G., Krämer, M., Benner, A., Bornhäuser, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7921 · Cited by 76 · see citing works
The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
Hong, M., & He, G. (2017) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2017-0002 · Cited by 75 · see citing works
Visconte, V., Tiu, R. V., & Rogers, H. J. (2014) · Blood Research · doi:10.5045/br.2014.49.4.216 · Cited by 71 · see citing works
Consequences of mutant TET2 on clonality and subclonal hierarchy
Hirsch, C. M., Nazha, A., Kneen, K. E., Abazeed, M. E., Meggendorfer, M., Przychodzen, B. P., Nadarajah, N., Ademà, V., Nagata, Y., Goyal, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0150-9 · Cited by 68 · see citing works
Mossner, M., Jann, J.-C., Nowak, D., Platzbecker, U., Giagounidis, A. A. N., Götze, K. S. S., Letsch, A., Haase, D. T., Shirneshan, K., Braulke, F., et al. (2016) · Leukemia · doi:10.1038/leu.2016.111 · Cited by 67 · see citing works
Zhang, L., McGraw, K. L., Sallman, D. A., & List, A. F. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1266625 · Cited by 67 · see citing works
Müller‐Thomas, C., Rudelius, M., Rondak, I., Haferlach, T., Schanz, J., Huberle, C., Schmidt, B., Blaser, R., Kremer, M., Peschel, C., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.104760 · Cited by 66 · see citing works
Loghavi, S., Kanagal‐Shamanna, R., Khoury, J. D., Medeiros, L. J., Naresh, K. N., Nejati, R., & Patnaik, M. M. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100397 · Cited by 65 · see citing works
Next‐generation sequencing – feasibility and practicality in haematology
Kohlmann, A., Großmann, V., Nadarajah, N., & Haferlach, T. (2013) · British Journal of Haematology · doi:10.1111/bjh.12194 · Cited by 65 · see citing works
Ribosome biogenesis and cancer: basic and translational challenges
Bustelo, X. R., & Dosil, M. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.10.003 · Cited by 65 · see citing works
Gaymes, T. J., Mohamedali, A. M., Patterson, M., Matto, N., Smith, A., Kulasekararaj, A. G., Chelliah, R., Curtin, N. J., Farzaneh, F., Shall, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.079251 · Cited by 64 · see citing works
Self-citationVolkert, S., Kohlmann, A., Schnittger, S., Kern, W., Haferlach, T., & Haferlach, C. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22151 · Cited by 63 · see citing works
Germing, U., Kobbe, G., Haas, R. R., & Gattermann, N. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0783 · Cited by 62 · see citing works
Falini, B., & Martelli, M. P. (2023) · American Journal of Hematology · doi:10.1002/ajh.26812 · Cited by 61 · see citing works
Hsu, J., Reilly, A., Hayes, B. J., Clough, C. A., Konnick, E. Q., Torok‐Storb, B., Gülsüner, S., Wu, D., Becker, P. S., Keel, S., et al. (2019) · Blood · doi:10.1182/blood.2018884338 · Cited by 60 · see citing works
Clinical decision-making and treatment of myelodysplastic syndromes
Hellström‐Lindberg, E., & Kröger, N. M. (2023) · Blood · doi:10.1182/blood.2023020079 · Cited by 59 · see citing works
Self-citationIntegration of Next-Generation Sequencing Into Clinical Practice: Are We There Yet?
Kohlmann, A., Grossmann, V., & Haferlach, T. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.008 · Cited by 57 · see citing works
Beličková, M., Veselá, J., Jonasova, A. T., Pejsova, B., Votavová, H., Merkerová, M. D., Zemanová, Z., Březinová, J., Mikulenková, D., Lauermannová, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9200 · Cited by 56 · see citing works
Targeting cereblon in hematologic malignancies
Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55 · see citing works
Genetics of Myelodysplastic Syndromes: New Insights
Graubert, T. A., & Walter, M. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.543 · Cited by 55 · see citing works
TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms
Martinez-Aviles, L. M., Besses, C., Álvarez‐Larrán, A., Torres, E., Serrano, S., & Bellosillo, B. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1330-0 · Cited by 55 · see citing works
Myelodysplastic Syndromes, Version 2.2015
Greenberg, P. L., Stone, R. M., Bejar, R. L., Bennett, J. M., Bloomfield, C. D., Borate, U., de Castro, C. M., Deeg, H. J., Dezern, A. E., Fathi, A. T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0038 · Cited by 55 · see citing works
Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms
McClure, R. F., Ewalt, M. D., Crow, J., Temple‐Smolkin, R., Pullambhatla, M., Sargent, R. L., & Kim, A. S. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.07.002 · Cited by 54 · see citing works
Anemia as the Main Manifestation of Myelodysplastic Syndromes
Santini, V. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.06.002 · Cited by 52 · see citing works
Lodé, L., Ménard, A., Flet, L., Richebourg, S., Loirat, M., Eveillard, M., Le Bris, Y., Godon, C., Theisen, O., Gagez, A.-L., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.181404 · Cited by 52 · see citing works
Cáceres, G., McGraw, K. L., Yip, B. H., Pellagatti, A., Johnson, J., Zhang, L., Liu, K., Zhang, L. M., Fulp, W. J., Lee, J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311055110 · Cited by 52 · see citing works
on behalf of the German MDS Study Group, Platzbecker, U., Braulke, F., Kündgen, A., Götze, K. S. S., Bug, G., Schönefeldt, C., Shirneshan, K., Röllig, C., Bornhäuser, M., et al. (2013) · Leukemia · doi:10.1038/leu.2013.26 · Cited by 52 · see citing works
Deletion 5q MDS: Molecular and therapeutic implications
Komrokji, R. S., Padron, E., Ebert, B. L., & List, A. F. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.10.013 · Cited by 52 · see citing works
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications
Grossmann, V., Roller, A., Klein, H., Weißmann, S., Kern, W., Haferlach, C., Dugas, M., Haferlach, T., Schnittger, S., & Kohlmann, A. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.003 · Cited by 52 · see citing works
- Authors
- Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., Hellström-Lindberg, E., & Mufti, G. J.
- Affiliations
- King's College London (GB)
- From the Department of Medicine, Center for Experimental Hematology, and Department of Pathology and Oncology, Karolinska Institutet, Stockholm, Sweden; King's College London School of Medicine, London, United Kingdom; and Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-20
- Volume
- 29
- Issue
- 15
- Pages
- 1971-1979
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2131256397
- Cited by
- 463
- References
- 33
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 26 · 2023: 23 · 2022: 27 · 2021: 31 · 2020: 27 · 2019: 33 · 2018: 28 · 2017: 37 · 2016: 34 · 2015: 44 · 2014: 38 · 2013: 47 · 2012: 26
- FWCI
- 28.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- TP53 mutation, myelodysplastic syndrome, del(5q), p53 expression, disease progression, cytogenetic response, clone size, disease heterogeneity
- MeSH terms
- Adult, Aged, Aged, 80 and over, Chromosome Deletion, Chromosomes, Human, Pair 5, Female, Humans, Male, Middle Aged, Myelodysplastic Syndromes, Peptide Fragments, Prognosis, Risk, Leukemia, Myeloid, Acute, Genes, p53, Tumor Suppressor Protein p53, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
